Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by
AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
04:55pm, Friday, 06'th Mar 2026
AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial
08:42am, Friday, 06'th Mar 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has reported its fourth quarter and full-year 2025 financial results, highlighting progress across several clinical programs targeting mental health disorders
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
07:00am, Friday, 06'th Mar 2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing
08:09am, Tuesday, 03'rd Mar 2026
The FDA has supported the Phase 3 design for BPL-003, an intranasal psychedelic-derived therapy for treatment-resistant depression AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC), a clinical-stage biotechnolo
Cathie Wood "Buys the Dip" in Baidu Stock -- Should You?
06:58am, Friday, 27'th Feb 2026
ARK Invest added to its position in Baidu (BIDU) while trimming exposure to several technology and industrial holdings following recent market moves.The investm
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial
09:51am, Thursday, 26'th Feb 2026
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has reported positive topline results from an exploratory Phase 2a trial evaluating its oral R-MDMA candidate, EMP-01, in adults with social anxiety disorder (S
AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data
09:49am, Thursday, 26'th Feb 2026
AtaiBeckley Inc. (NASDAQ: ATAI) on Thursday shared topline results from an exploratory Phase 2a trial of EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder.
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
07:00am, Thursday, 26'th Feb 2026
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profile EMP-01 demonstrated a clinically meaningful placebo-adju
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
07:00am, Friday, 20'th Feb 2026
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by d
Asara Resources extends high-grade corridor at Massan with 54m at 2.3 g/t gold
05:51am, Friday, 20'th Feb 2026
Asara Resources Ltd (ASX:AS1, OTC:GMRMF) has extended high-grade gold mineralisation at its Massan deposit within the company’s flagship Kada Gold Project...
US economy grew at half the expected pace in the fourth quarter, dragging futures lower
03:55am, Friday, 20'th Feb 2026
US stock futures slipped further into negative territory after data showed the American economy expanded at an annualised rate of just 1.4% in the final...
AtaiBeckley names Michael Faerm as finance chief
08:27am, Thursday, 19'th Feb 2026
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to adva
AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies
01:00pm, Wednesday, 21'st Jan 2026
Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful tailwind for the broader psychedelics sector, w
